| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/28/2006 | CA2601880A1 Method for interfering with blood coagulation by modulating cross-beta structures fibril formation |
| 09/28/2006 | CA2601653A1 Methods and compositions for derepression of iap-inhibited caspase |
| 09/28/2006 | CA2601592A1 Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| 09/28/2006 | CA2601540A1 Use of fibrous tissue inducing proteins for hernia repair |
| 09/28/2006 | CA2601377A1 Reduction of postoperative pain medication |
| 09/28/2006 | CA2601373A1 Fine particulate preparation comprising complex of nucleic acid molecule and collagen |
| 09/28/2006 | CA2601360A1 Sclerostin and the inhibition of wnt signaling and bone formation |
| 09/28/2006 | CA2600869A1 Compounds having activity in correcting mutant-cftr processing and uses thereof |
| 09/27/2006 | EP1705487A2 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 09/27/2006 | EP1705248A1 Fusion proteins comprising an angiostatin moiety and their use in anti-tumour treatment |
| 09/27/2006 | EP1705190A2 Peptide derivatives |
| 09/27/2006 | EP1705189A1 Feline hepatocyte growth factor |
| 09/27/2006 | EP1705188A1 Modified KAP familiy polypeptides and their use in cosmetics |
| 09/27/2006 | EP1705184A1 Treatment of neoplastic diseases using a combination of plasminogen activators and sulfhydryl donors |
| 09/27/2006 | EP1705182A1 Antitumoral and antiviral peptides |
| 09/27/2006 | EP1704871A1 Iron supplement and utilization of the same |
| 09/27/2006 | EP1704869A1 VR-2332 viral nucleotide sequence and methods of use |
| 09/27/2006 | EP1704868A1 HLA binding peptides and their uses |
| 09/27/2006 | EP1704867A1 Cross-beta structures on microbial organisms |
| 09/27/2006 | EP1704866A2 TGFbeta superfamily proteins for biological anchoring of connective tissue to bone |
| 09/27/2006 | EP1704414A2 Induction of apoptosis via arts-iap complexes |
| 09/27/2006 | EP1704254A2 Methods of using peroxisome proliferator-activated receptor alpha target genes |
| 09/27/2006 | EP1704250A2 Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
| 09/27/2006 | EP1704239A1 Integrase fusion proteins and their use with integrating gene therapy |
| 09/27/2006 | EP1704234A2 Production of glucagon like peptide 2 and analogs |
| 09/27/2006 | EP1704227A1 Immortalized hepatocytes |
| 09/27/2006 | EP1704165A1 Novel glp-1 compounds |
| 09/27/2006 | EP1704164A2 Interleukin-11 fusion proteins |
| 09/27/2006 | EP1704142A1 Protease inhibitors |
| 09/27/2006 | EP1703916A2 Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same |
| 09/27/2006 | EP1703915A2 Methods of using cgrp for cardiovascular and renal indications |
| 09/27/2006 | EP1703907A2 Compositions and methods to treat recurrent medical conditions |
| 09/27/2006 | EP1703899A2 Stabilised compositions of factor vii polypeptides |
| 09/27/2006 | EP1703895A2 Controlled release cgrp delivery composition for cardiovascular and renal indications |
| 09/27/2006 | EP1549334B1 Pharmaceutical composition comprising a retro-inverso isomer peptide |
| 09/27/2006 | EP1482986B1 Method for determining effect of a clostridial toxin upon a muscle |
| 09/27/2006 | EP1461062B1 Composition and method for treating chronic allograft rejection |
| 09/27/2006 | EP1374899B1 Remedies for post-traumatic stress disorder |
| 09/27/2006 | EP1265605B1 Pharmaceutical compositions comprising beta-turn peptidomimetic cyclic compounds |
| 09/27/2006 | EP1251832B1 Shell-and-core dosage form approaching zero-order drug release |
| 09/27/2006 | EP1196433B1 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN ALPHA v BETA 6 |
| 09/27/2006 | EP1180016B1 Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
| 09/27/2006 | EP1173222B1 Conjugate having a cleavable linkage for use in a liposome |
| 09/27/2006 | EP1012303B1 Factor x deletion mutants and analogues thereof |
| 09/27/2006 | EP0951286B1 Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations |
| 09/27/2006 | EP0889733B1 Stabilised growth hormone formulation and method of preparation thereof |
| 09/27/2006 | EP0759786B1 Somatostatin binding peptide-metal chelate conjugates |
| 09/27/2006 | CN1839203A FVII or FVIIa GLA domain variants |
| 09/27/2006 | CN1839156A Separation of polypeptides comprising a racemized amino acid |
| 09/27/2006 | CN1839155A Purification of glucagon-like peptides |
| 09/27/2006 | CN1839150A Compositions of lipopeptide antibiotic derivatives and methods of use thereof |
| 09/27/2006 | CN1839149A Peptides which can bind to transforming growth factor beta 1 (tgf-beta1) |
| 09/27/2006 | CN1839148A Cytotoxic depsipeptides |
| 09/27/2006 | CN1838966A Use of human growth hormone in multiple system atrophy |
| 09/27/2006 | CN1838965A Drug for cancer therapy |
| 09/27/2006 | CN1838964A Treatment and prevention of pulmonary conditions |
| 09/27/2006 | CN1838962A Injection of bone marrow-derived cells and medium for angiogenesis |
| 09/27/2006 | CN1838954A Glycogen synthase kinase-3 inhibitors |
| 09/27/2006 | CN1837241A Interactive molecular binding domain of angiogenin and LIM protein |
| 09/27/2006 | CN1837240A Interactive molecular binding domain of angiogenin and lambda crystallin |
| 09/27/2006 | CN1837239A Polypeptide growth factor copolymer and its preparation method and use |
| 09/27/2006 | CN1837237A Recombinant human interleukin1 receptor antagon (rhIL-1ra) with low pyrogen and its high efficiency preparation process |
| 09/27/2006 | CN1837236A Polypeptide of extracellular domain of sodium pump and use in preparation of drugs for adjusting the activity of sodium pump |
| 09/27/2006 | CN1837205A Process for the preparation of pyrazolopyridine tartrates |
| 09/27/2006 | CN1836732A Two kinds of novel angiogenesis-inhibiting medicine and its uses in preventing and treating tumour |
| 09/27/2006 | CN1836728A Use of neutral proteinase in treating burn |
| 09/27/2006 | CN1836727A Chymotrypsin-parenzyme oral ulcer preparation |
| 09/27/2006 | CN1836726A Oral liquid for treating drug addict |
| 09/27/2006 | CN1836669A Method for preparing sheep placenta extract |
| 09/27/2006 | CN1276974C Gsk3 polypeptides |
| 09/27/2006 | CN1276928C Cell apoptosis regulating protein related with heart failure |
| 09/27/2006 | CN1276748C Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 09/26/2006 | US7112667 Sequences of an Ih ion channel and use thereof |
| 09/26/2006 | US7112666 Von Willebrand Factor (Vwf)-cleaving protease |
| 09/26/2006 | US7112660 Modified cytokine |
| 09/26/2006 | US7112659 Given DNA sequence; Fc immunoglobulin region attached; transforming cell; use in treating obesity; isolated human leptin fusion protein; for treating excess weight in an individual or animals, including modulation of and/or fat deposition |
| 09/26/2006 | US7112655 JTT-1 protein and methods of inhibiting lymphocyte activation |
| 09/26/2006 | US7112654 Ligand for vascular endothelial growth factor receptor |
| 09/26/2006 | US7112653 Composition and method for preserving progenitor cells |
| 09/26/2006 | US7112597 5-(Substituted thiazolylethoxy)indaneacetic acid derivatives, used in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases |
| 09/26/2006 | US7112590 Anticoagulant for mammals |
| 09/26/2006 | US7112578 Methods and compositions for treatment of inflammatory disease |
| 09/26/2006 | US7112572 Multivalent metal salts of boronic acids |
| 09/26/2006 | US7112571 Peptide Y-2 |
| 09/26/2006 | US7112570 Central nervous system disorders; brain disorders |
| 09/26/2006 | US7112569 Particularly when isolated from Streptomyces sp. KK565 deposited under Accesion NO: KCCM-10485 or encoded by a specific polynucleotide; used to treat neurodegenerative disorders like Alzheimer's disease. |
| 09/26/2006 | US7112568 an anti-allergic agent, comprising a molecule having at least a first segment competent for importation of the molecule into mast cells, and a second segment for having an anti-allergic effect within the mast cells |
| 09/26/2006 | US7112567 reactive entity (maleimide) coupled to the peptide conjugated to blood protein such as immunoglobulins, including IgG and IgM, serum albumin, ferritin, steroid binding proteins, transferrin, thyroxin binding protein, alpha -2-macroglobulin, haptoglobin, etc. |
| 09/26/2006 | US7112566 Treating narcolepsy or cataplexy in a mammal by administering hypocretin-1 to a peripheral tissue via injection, whereby the hypocretin-1 crosses the blood brain barrier of the mammal and preferably monitoring the patient's response |
| 09/26/2006 | US7112565 Stabilized pharmaceutical composition in lyophilized form |
| 09/26/2006 | US7112564 Biodegradable glucosaminemuramyl peptides for apoptosis modulation |
| 09/26/2006 | US7112563 Therapies using hemoproteins |
| 09/26/2006 | US7112562 Insulin conjugates and methods of use thereof |
| 09/26/2006 | US7112561 Pharmaceutical compositions and methods for insulin treatment |
| 09/26/2006 | US7112560 Angiogenically effective unit dose of FGF-2 and method of use |
| 09/26/2006 | US7112430 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| 09/26/2006 | US7112427 Protein comprising mitogenic kinase activity for identifying modulators of inflammation, apoptosis and cell proliferation; antiproliferative agents |
| 09/26/2006 | US7112421 Nucleic acids encoding BAFF receptor, chimeric proteins and methods and compositions related thereto |
| 09/26/2006 | US7112419 For suppression of hepatocellular carcinoma; genetic engineering |
| 09/26/2006 | US7112414 Masp-2, a complement-fixing enzyme, and uses for it |